Moreover, our findings that mice deficient in miR-29a/b1 develop cardiovascular abnormalities and that both mutant mice and HF patients exhibit PGC1α overexpression suggest that miRNA replacement therapies could be beneficial for these patients, as proposed for other pathologies associated with miRNA deregulation [15,55,56]. This evidence concerns the gene PPARGC1A and hydrops fetalis.